Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer Po HuPeng WanYang Pan Original Article – Cancer Research 19 August 2022 Pages: 553 - 566
Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer Érica Romão PereiraLaís Capelasso Lucas PinheiroRoberta Losi Guembarovski Original Article – Cancer Research 25 August 2022 Pages: 567 - 577
HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria Qi SunQi LiXiaohong Pu Original Article – Cancer Research Open access 26 August 2022 Pages: 579 - 592
Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer Wei TanShiyi LiuYanxiang Cheng Original Article – Cancer Research 01 September 2022 Pages: 593 - 608
The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model Haiping HeYulin CenLilei Peng Original Article – Cancer Research 06 September 2022 Pages: 609 - 622
Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development Yi-Fei LiQiong-Qiong HouLin Li Original Article – Cancer Research 14 October 2022 Pages: 623 - 637
NOD2 inhibits the proliferation of esophageal adenocarcinoma cells through autophagy Xiaozhi LiSuo LiuTao Liu Original Article – Cancer Research Open access 31 October 2022 Pages: 639 - 652
TMEM196 inhibits lung cancer metastasis by regulating the Wnt/β-catenin signaling pathway Jianping ChenDandan WangJinyi Liu Original Article – Cancer Research 10 November 2022 Pages: 653 - 667
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance Lucien TorlotAnna JarzabAndreas Jung Original Article – Cancer Research Open access 19 November 2022 Pages: 669 - 682
Hyperbaric oxygen enhanced the chemotherapy of mitochondrial targeting molecule IR-780 in bladder cancer Chongxing ShenXiaofeng YueWeibing Li Original Article – Cancer Research 27 November 2022 Pages: 683 - 699
Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients Jiuhong WangHang JiangJingjing Li Original Article – Cancer Research 01 December 2022 Pages: 701 - 708
Tumor characteristics, therapy, and prognosis in young breast cancer patients ≤ 35 years Naaja-Kristin EckardtAtanas IgnatovHolm Eggemann Original Article – Cancer Research 19 December 2022 Pages: 709 - 719
Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data Jutta EngelRenate EckelDieter Hölzel Review – Clinical Oncology Open access 20 December 2022 Pages: 721 - 735
HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events Ning JiangYue YuNing Li Review – Clinical Oncology 20 January 2023 Pages: 737 - 747
Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era Dai OgataKeita TsutsuiNaoya Yamazaki Original Article – Clinical Oncology 03 February 2022 Pages: 749 - 755
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study Xinqing LinHaiyi DengChengzhi Zhou Original Article – Clinical Oncology 10 February 2022 Pages: 757 - 764
Burnout among German oncologists: a cross-sectional study in cooperation with the Arbeitsgemeinschaft Internistische Onkologie Quality of Life Working Group Madeleine HelaßGeorg Martin HaagImad Maatouk Original Article – Clinical Oncology Open access 13 February 2022 Pages: 765 - 777
Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial Yanshuo CaoMing LuLin Shen Original Article – Clinical Oncology Open access 15 February 2022 Pages: 779 - 789
MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors Stefan SchönbergerMahsa Mir MohseniDagmar Dilloo Original Article – Clinical Oncology Open access 16 February 2022 Pages: 791 - 802
Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration Katharina RöhrmoserAtanas IgnatovThomas Papathemelis Original Article – Clinical Oncology 18 February 2022 Pages: 803 - 810
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma Max S. ToppHerbert EradatIzidore S. Lossos Original Article – Clinical Oncology Open access 18 February 2022 Pages: 811 - 817
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial Chao SunYunpeng LiuKewei Ma Original Article – Clinical Oncology 22 February 2022 Pages: 819 - 831
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy Julia EckardtChristopher SchroederAndrea Forschner Original Article – Clinical Oncology Open access 22 February 2022 Pages: 833 - 840
Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer Darren M. C. PoonBin YangJing Yuan Original Article – Clinical Oncology 24 February 2022 Pages: 841 - 850
The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study Katharina AnicChristin AltehoeferMarco Johannes Battista Original Article – Clinical Oncology Open access 25 February 2022 Pages: 851 - 863
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study Pınar GursoyAli Murat TatliPerran Fulden Yumuk Original Article – Clinical Oncology 05 April 2022 Pages: 865 - 875
Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team Christopher FanAhyoung KimAmy K. Kim Research 14 September 2022 Pages: 877 - 883
Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database Fanggui ShaoLiqun LingYumin Wang Research 27 December 2022 Pages: 885 - 899
Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma Sisi LiuMingxin LiFusheng Liu Research 28 August 2022 Pages: 901 - 912
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic Volker ArndtDaniela DoegeMichael Baumann Letter to the Editor Open access 14 October 2022 Pages: 913 - 919
Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules Zhenzhen WuYanli WangXin Zhao Correspondence 26 September 2022 Pages: 921 - 927
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years Sabine KürzelAndré‑René BlaudszunMathias Hänel Correction 09 September 2022 Pages: 929 - 931